TABLE 2.
Model input parameters.
| Model input | Base case | Range | Distribution | Reference |
|---|---|---|---|---|
| Drug costs | ||||
| Tislelizumab (100 mg) | 427.73 | 320.80–427.73 | Gamma | YAOZH |
| Docetaxel (20 mg) | 21.60 | 7.98–144.54 | Gamma | YAOZH |
| Irinotecan (100 mg) | 119.39 | 87.76–284.56 | Gamma | YAOZH |
| Paclitaxel (30 mg) | 10.86 | 5.60–72.17 | Gamma | YAOZH |
| Investigator’s choice of chemotherapies | ||||
| Docetaxel cases (%) | 53 (20.70%) | — | Dirichlet | Shen et al. (2022) |
| Irinotecan cases (%) | 118 (46.10%) | — | Dirichlet | Shen et al. (2022) |
| Paclitaxel cases (%) | 85 (33.20%) | — | Dirichlet | Shen et al. (2022) |
| Body surface area (BSA, m2) | 1.72 | 1.50–1.90 | Gamma | Zhang et al. (2021) |
| Follow-up cost | 7.46 | 6.52–8.47 | Gamma | Cai D.et al. (2021) |
| Best supportive care cost | 167.29 | 133.83–200.75 | Gamma | Cai H.et al. (2021) |
| End-of-life care cost | 1460.30 | 1168.24–1752.36 | Gamma | Cai D.et al. (2021) |
| Utility | ||||
| PFS | 0.741 | 0.593–0.889 | Beta | Zhang et al. (2020) |
| PD | 0.581 | 0.465–0.697 | Beta | Zhang et al. (2020) |
| Discount | 5% | 0%–8% | Constant | |